MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtcvs.2023.09.047

Медицинская библиотека · The Journal of thoracic and cardiovascular surgery · 2023

Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis.

Beaver Thomas, Bavaria Joseph E, Griffith Bartley, Svensson Lars G, Pibarot Philippe, Borger Michael A, Sharaf Omar M, Heimansohn David A, Thourani Vinod H, Blackstone Eugene H, Puskas John D, COMMENCE Trial Investigators

Клиническое исследованиеСтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVE

As bioprosthetic aortic valve replacement (AVR) extends to younger cohorts, tissue durability is of paramount importance. We report 7-year outcomes from an AVR bioprosthesis utilizing novel tissue.

METHODS

This was an international investigational device exemption trial for novel AVR with annual follow-up and a subset re-consented at 5 years for extended 10-year follow-up. Safety end points and echocardiographic measurements were adjudicated by an independent clinical events committee and by a dedicated core laboratory, respectively.

RESULTS

Between January 2013 and March 2016, 689 patients underwent AVR with the study valve. Mean age was 66.9 ± 11.6 years, Society of Thoracic Surgeons risk score was 2.0% ± 1.8%, and 74.3% of patients were New York Heart Association functional class II and III. Five-year follow-up was completed by 512 patients, and 225 re-consented for extended follow-up. Follow-up duration was 5.3 ± 2.2 years (3665.6 patient-years), and 194 and 195 patients completed 6- and 7-year follow-ups, respectively. One-, 5-, and 7-year freedom from all-cause mortality was 97.7%, 89.4%, and 85.4%, respectively. Freedom from structural valve deterioration at 7 years was 99.3%. At 7 years, effective orifice area and mean gradients were 1.82 ± 0.57 cm2 (n = 153), and 9.4 ± 4.5 mm Hg (n = 157), respectively. At 7 years, predominantly none (96.8% [152 out of 157]) or trivial/trace (2.5% [4 out of 157]) paravalvular regurgitation and none (84.7% [133 out of 157]) or trivial/trace (11.5% [18 out of 157]) transvalvular regurgitation were observed.

CONCLUSIONS

We report the longest surgical AVR follow-up with novel tissue in an investigational device exemption trial utilizing an independent clinical events committee and an echocardiography core laboratory. This tissue demonstrates excellent outcomes through 7 years and is the benchmark for future surgical and transcatheter prostheses.

Для цитирования: Beaver Thomas, Bavaria Joseph E, Griffith Bartley, Svensson Lars G, Pibarot Philippe, Borger Michael A, Sharaf Omar M, Heimansohn David A, Thourani Vinod H, Blackstone Eugene H, Puskas John D, COMMENCE Trial Investigators. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis.. The Journal of thoracic and cardiovascular surgery. 2023. DOI: 10.1016/j.jtcvs.2023.09.047.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.